Search Login Register

panitumumab (Vectibix) Summary

Description: antibody that blocks receptors for epidermal growth factor; approved for advanced colon cancer

Also Known As: Vectibix; ABX-EGF MAb; ABX-EGF monoclonal antibody; Amgen brand of panitumumab; panitumumab antibody, human Show All >>

Networked: 546 relevant articles (94 outcomes, 160 trials/studies) for this Drug

Key Diseases for which panitumumab is Relevant

  1. Colorectal Neoplasms (Colorectal Cancer) : 64 outcomes 94 studies in 351 results
  2. Neoplasms (Cancer) : 25 outcomes 44 studies in 184 results
  3. Sarcoma (Soft Tissue Sarcoma) : 4 outcomes 4 studies in 10 results
  4. Disease Progression : 3 outcomes 8 studies in 27 results
  5. Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) : 2 outcomes 5 studies in 16 results
Show All >>

Drugs Related to panitumumab

  1. cetuximab (Erbitux)
  2. bevacizumab
  3. Monoclonal Antibodies
  4. Epidermal Growth Factor Receptor (EGF Receptor)
  5. oxaliplatin (Eloxatin)
  6. irinotecan (Camptosar)
  7. Fluorouracil (Carac)
  8. Leucovorin (Folinic Acid)
  9. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
  10. Antibodies
Show All >>

Therapies Related to panitumumab

  1. Drug Therapy (Chemotherapy)
  2. Heterologous Transplantation (Xenotransplantation)
  3. Combination Drug Therapy (Combination Chemotherapy)
  4. Molecular Targeted Therapy
  5. Radiotherapy
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.